Amgen Buys into BeiGene

04-NOV-19

Our biotech pharma investment Amgen has made some interesting moves in the last week. As long-time holders of this stock know, it owns a wide portfolio of patented drugs for treating inflammation and arthritis, cardiovascular disease, cancer, migraines, bone injuries and skin disorders.


Read more...

Amgen Q3 - Biosimilar Continues to Grow

30-OCT-19

The world's largest biotech company, Amgen released its third-quarter earnings that beat the streets expectations. The company saw strong volume growth for the seventh consecutive quarter which can be attributable to new drug launches like migraines drug Aimovig and the launch of biosimilars including Kanjinti for breast cancer.


Read more...

Amgen Buys Otezla

27-AUG-19

There was good news yesterday from our recommended portfolio holding, biotech pharma company Amgen. They announced that they will buy the psoriasis drug Otezla from Celgene for $13.4 billion in cash.


Read more...

Amgen Q2 - Beats Expectations

01-AUG-19

What's going on at Amgen? This biotech company is also widely held in our client base, and its share price has underperformed a bit lately. The stock price reached $210 late last year, but has since drifted lower to around $180 per share.


Read more...

Amgen's New Lung and Colon cancer

27-JUN-19

Our most important role at Vestact is to closely monitor the stocks that our clients own. Pharmaceutical giant Amgen is held by most of our New York customers. Its share price has been drifting around lately, and closed at $183.17 last night. In fact, there is lots of good stuff going on at Amgen. It's just that some of their current big-selling drugs are reporting declining sales, and their newer ones are taking time to gain traction. Here are two stories that underline why this stock is a good one to own.


Read more...

Amgen Q1 - Pause Before New Drugs Take Off

06-MAY-19

Last week Vestact's direct exposure to the pharmaceutical industry, Amgen, reported their Q1 numbers. Currently, the company is in a bit of no-mans land, where some of their big-name patents have recently expired, and the company is waiting for their new big-name drugs to ramp up in scale.


Read more...

Amgen's Fight with Novartis

09-APR-19

Vestact recommended pharma company Amgen has an extremely promising drug called Erenumab (trade name Aimovig) which is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraines. It was approved by the US FDA in 2018.


Read more...

Amgen Q4 - Mix of Old and New Drugs

04-FEB-19

Last week our favoured biotech stock, Amgen, released results for the fourth quarter and full year 2018. As we have alluded to before, Amgen is going through a phase where a few of their blockbuster drugs are slowing down because of off-patent competition. At the same time they are pushing new exciting drugs into the market. That is not always as easy as it sounds, even if you assume the drug works really well. You still need to convince the doctors, insurers and hospitals to endorse the product.


Read more...

Amgen Q3 - Beats expectations

31-OCT-18

Amgen is another core holding in Vestact US portfolios, and had results out after the bell last night. As you know, it is one of the world's leading biotechnology companies, with a focus on cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.


Read more...

Amgen invests in Oxford Nanopore

24-OCT-18

When there is a lot going on in the general news, it's useful to refocus on company specific updates. After all, we invest in actual enterprises which do useful things in the real world, and get paid.


Read more...

Amgen's new Drugs

25-SEP-18

Amgen is a core holding in Vestact US portfolios. It is one of the world's leading biotechnology companies, and it closed at a lifetime high of $207.21 last night, giving it a market capitalisation of $134 billion.


Read more...

Amgen 2Q - strong pipeline

30-JUL-18

On Thursday the world's largest biotech firm Amgen reported a better-than-expected set of numbers for their second quarter. Amgen raised their full-year forecast, as the company sees more growth stemming from Prolia, an osteoporosis drug, and Repatha, a drug that fights bad cholesterol.


Read more...

Amgen 1Q numbers - in with the new

26-APR-18

We are deep into quarterly US earnings season now, and what an exciting time it is! It's great to get detailed updates from all of our core Vestact portfolio holdings, and to see the market reactions.


Read more...

Amgen FY numbers - strong line up

05-FEB-18

Amgen's fourth-quarter results came out late last week. The stock price has done pretty well in the last three months, almost getting to $200 per share. It's at $187 per share now, giving the company a market capitalisation of $135.8 billion.


Read more...

Amgen 3Q numbers - Beat expectations

26-OCT-17

On Wednesday we had 3rd quarter results from Amgen. Remember these guys discover, develop and manufacture various human therapeutics. When looking at this company, all focus needs to be on their portfolio of therapies; what they cure, competition, FDA approval, medical aid adoption, doctor adoption, side effects, how the therapy is administered, regulation and many more factors. Fortunately, Amgen has a market cap of $130bn (30% bigger than Naspers) and boasts a portfolio of more than 13 mainstream products with annual sales ranging from $150m to $6bn.


Read more...

Older stories...

Newsletter Sign Up

Sign up for our free daily market newsletter.

Paul Theron's Tweets

Byron Lotter's Tweets

Michael Treherne's Tweets

Bright Khumalo's Tweets